Anticholinergics a Key Contributor to Cognitive Impairment medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Mark Askren is an IT executive and leadership coach with 35 years of higher education experience. He most recently served as Vice President and CIO for the University of Nebraska. During this period he was elected to the EDUCAUSE Board of Directors, served as chair of the Internet2 Community Engagement Program Advisory Group, and was a member of the Big Ten Academic Alliance for IT. Prior to that he served as Assistant Vice Chancellor for Administrative Computing Services at the University of California, Irvine, where he was also a member of the University of California’s Information Technology Leadership Council. Mark also held the positions of Assistant Vice President for Application Development and Data Management at the University of Illinois, and Assistant Dean for Information Technology at the UC San Diego School of Medicine.
E-Mail
IMAGE: Debanjan Dhar, PhD, is co-senior author of the study and assistant professor in the Department of Medicine, Division of Gastroenterology at UC San Diego School of Medicine. view more
Credit: UC San Diego Health Sciences
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD patients are at higher risk of developing Non-alcoholic steatohepatitis (NASH), which causes severe and chronic liver inflammation, fibrosis and liver damage. A patient with NASH is believed to be at high risk for developing a form of liver cancer called hepatocellular carcinoma (HCC).
Apart from lifestyle interventions, there are currently no approved treatments for NASH. A liver transplant is sometimes the only remedy.
Noted Researcher and Scientific Leader Jack E. Dixon Retires
In a career spanning almost half-a-century, Dixon pioneered new discoveries and advanced science at both UC San Diego and the Howard Hughes Medical Institute
Jack E. Dixon, PhD, whose distinguished and varied 48-year career ranged from helping reveal how cells communicate and fundamental processes of disease to becoming a renowned scientific leader, including terms as associate vice chancellor of scientific affairs at UC San Diego School of Medicine and as chief scientific officer at Howard Hughes Medical Institute, is retiring.
Jack Dixon, PhD, a renowned scientific leader at UC San Diego School of Medicine and Howard Hughes Medical Institute, is retiring after a distinguished 48-year career.
The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a $5 million grant to researchers at University of California San Diego School of Medicine to conduct a first-in-human Phase 1 clinical trial of a gene therapy for treating Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.